ReAlta Life Sciences
Linda Dell, PMP, has been a member of the ReAlta team since April 2020. She brings over 20 years of documented success developing and executing on key strategies and new initiatives for multimillion-dollar, global life science organizations. Prior to joining ReAlta, Ms. Dell held a senior management role in strategy and portfolio advancement for Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company focused on delivering injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, she was involved in all facets of the drug development process including product selection, portfolio management, strategic planning, business development, due diligence for both in-licensing and out-licensing, and project management. She served as alliance manager for the firm’s strategic partnerships with Teva Pharmaceuticals and SymBio Pharmaceuticals. Prior to Eagle, Ms. Dell held similar project management and program leadership roles at Taro Pharmaceuticals, Cambrex Corporation, and Celgene Corporation. Ms. Dell has a B.S. in Chemical Engineering from Purdue University, an MBA from Georgetown University, and is a certified Project Management Professional (PMP).
This person is not in any offices
ReAlta Life Sciences
ReAlta Life Sciences, Inc. is an early stage pharmaceutical company incorporated in late, 2018, and located in Norfolk, Virginia. ReAlta was initially formed as a joint venture between Children’s Hospital of The King’s Daughters, Children’s Specialty Group (170 multispecialty pediatricians) and Eastern Virginia Medical School. ReAlta is dedicated to addressing life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms. To support this mission, ReAlta has developed a New Class of Drugs that can address unmet medical needs through unique Multi-Modal Therapeutic Capabilities.